Human Papillomavirus (HPV) Molecular Detection with Genotyping [Featured Topic]

To better accommodate important updates in the screening guidelines for HPV, an infection present in 20 million people in the United States and resulting in 6.2 million new infections per year, Mayo Medical Laboratories now offers testing for the detection of high-risk HPV (hrHPV), with genotyping for HPV-16 and HPV-18.

Advantages of this new test:

  • 3 -in-1 testing for every sample: High-risk HPV detection (14 high-risk types) with specific genotyping for HPV-16 and HPV-18
  • Enables women with positive results for HPV-16 and/or HPV-18 to be referred to colposcopy right away
  • Performed on cervical/endocervical and vaginal samples collected in ThinPrep or SurePath media

Learn more about HPV testing at Mayo Medical Laboratories.



Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.